$1.41
2.08% yesterday
Nasdaq, Aug 26, 10:00 pm CET
ISIN
US92023M1018
Symbol
GRI

Vallon Pharmaceuticals Inc Stock price

$1.41
-0.73 34.11% 1M
-6.79 82.80% 6M
-12.67 89.99% YTD
-7.22 83.66% 1Y
-19,676.43 99.99% 3Y
-349,001.79 100.00% 5Y
-349,001.79 100.00% 10Y
-349,001.79 100.00% 20Y
Nasdaq, Closing price Tue, Aug 26 2025
-0.03 2.08%
ISIN
US92023M1018
Symbol
GRI
Industry

Key metrics

Basic
Market capitalization
$3.6m
Enterprise Value
$340.0k
Net debt
positive
Cash
$3.3m
Shares outstanding
530.0k
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
3.0
Financial Health
Equity Ratio
70.3%
Return on Equity
-248.0%
ROCE
-745.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-9.4m | $-13.3m
EBIT
$-9.4m | $-12.1m
Net Income
$-11.3m | $-2.2m
Free Cash Flow
$-8.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
23.6% | -61.8%
EBIT
23.6% | -46.8%
Net Income
11.7% | 78.3%
Free Cash Flow
23.3%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-21.5
FCF per Share
$-15.4
Short interest
7.1%
Employees
4
Rev per Employee
$0.0
Show more

Is Vallon Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Vallon Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

5x Buy
83%
1x Hold
17%

Analyst Opinions

6 Analysts have issued a Vallon Pharmaceuticals Inc forecast:

Buy
83%
Hold
17%

Financial data from Vallon Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.92 4.92
40% 40%
-
- Research and Development Expense 4.48 4.48
11% 11%
-
-9.39 -9.39
24% 24%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -9.40 -9.40
24% 24%
-
Net Profit -11 -11
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vallon Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vallon Pharmaceuticals Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Live video webcast on Wednesday, August 20 th at 2:20 PM ET LA JOLLA, CA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, that it will present at the Webull Financial Corporate Connec...
Neutral
GlobeNewsWire
26 days ago
Access the “What This Means” segment here
Neutral
GlobeNewsWire
about one month ago
– Video webcast now available on-demand LA JOLLA, CA, July 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced Marc Hertz, PhD, President, Chief Executive Officer and Director ...
More Vallon Pharmaceuticals Inc News

Company Profile

Vallon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on the development and commercialization of proprietary biopharmaceutical products. The firm's primary product is Abuse-Deterrent Amphetamine Immediate and its product pipeline includes ADAIR, ADMIR, ADHD, and Narcolepsy. The company was founded by David C. Baker on January 11, 2018 and is headquartered in Philadelphia, PA.

Head office United States
CEO W. Hertz
Employees 4
Founded 2009
Website www.gribio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today